Jonas Schoendube
Director/Board Member at Cytena Bioprocess Solutions
Profile
Jonas Schoendube was the founder and former Chief Executive Officer of Cytena GmbH, which was founded in 2014.
He is currently a Director at Cytena Bioprocess Solutions.
He previously worked as a Manager-Business Area Biosciences at BICO Group AB.
Dr. Schoendube holds a doctorate from the University of Freiburg and a graduate degree from the Swiss Federal Institute of Technology.
Jonas Schoendube active positions
| Companies | Position | Start |
|---|---|---|
| Cytena Bioprocess Solutions | Director/Board Member | - |
Former positions of Jonas Schoendube
| Companies | Position | End |
|---|---|---|
cytena GmbH
 cytena GmbH BiotechnologyHealth Technology cytena GmbH develops a device for separating of single cells. It has developed a device called cy-Clone to separate single cells and these single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research, the cy-Clone is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate. The company was founded by Peter Koltay, Benjamin Steimle, Jonas Schoendube and Andre Gross in August 2014 and is headquartered in Freiburg, Germany. | Chief Executive Officer | 2021-04-30 |
| BICO GROUP AB | Corporate Officer/Principal | - |
Training of Jonas Schoendube
| University of Freiburg | Doctorate Degree |
| Swiss Federal Institute of Technology | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BICO GROUP AB | Health Technology |
| Private companies | 2 |
|---|---|
cytena GmbH
cytena GmbH BiotechnologyHealth Technology cytena GmbH develops a device for separating of single cells. It has developed a device called cy-Clone to separate single cells and these single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research, the cy-Clone is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate. The company was founded by Peter Koltay, Benjamin Steimle, Jonas Schoendube and Andre Gross in August 2014 and is headquartered in Freiburg, Germany. | Health Technology |
| Cytena Bioprocess Solutions |
- Stock Market
- Insiders
- Jonas Schoendube
